About
A global FMT service company.
JCY Bio operates two brands — aFMT (clinical, to hospital) and SereneSwift (consumer, gut-brain probiotic) — pursuing Microbiome-as-a-Drug across CNS (depression & mood disorders) and oncology (ICI sensitization & anti-metastasis). We were incubated by a state laboratory and run our own P2 + GMP manufacturing.
Clinical · To Hospital
aFMT
Industrialized FMT 3.0 for hospitals and research partners.
Explore aFMT →Consumer · Gut-Brain Probiotic
SereneSwift
Medical-grade gut-brain probiotics for everyday emotional balance.
Explore SereneSwift →Milestones
-
2023
Debut at Shenzhen Biomedical Industry Week; launched the FMT 3.0 "Pro" capsule.
-
2024
Global-first complete remission in Stage IVB pMMR/MSS colorectal cancer (Cureus); peer-reviewed SCI publication.
-
2024
Contributed to the China expert consensus on FMT for pediatric autism spectrum disorder.
-
2025
Selected to Shenzhen’s import/export special-items whitelist — one of 5 pharma firms citywide.
-
2025
Ulcerative colitis consensus marks the move toward standardized FMT practice.
-
2026
FMT-in-ALS research presented at the Greater Bay Area Brain Science Forum.
Leadership & team
Founder
Dr. Li Xiaozheng
- · Invited speaker, Greater Bay Area Brain Science Forum
- · Keynote speaker, Shenzhen Biomedical Industry Week
- · Drives FMT 3.0 from research to clinic to consumer
- · Focus: Microbiome × AI for depression, oncology and the gut-brain axis
Team
80% researchers
A team combining top-university research, state-lab science and industrial clinical experience — built for both rigorous R&D and real-world delivery.
Locations
-
Office
Rm 503, Shuzhi Space, Block B, Qianhai Hongrongyuan Center, Nanshan, Shenzhen, China
-
Manufacturing
Pingshan, Shenzhen, China
Work with us.
We’re building the consumer brand (SereneSwift) and the clinical platform (aFMT) in parallel. Roles span product, brand, research and clinical operations.